Literature DB >> 24080613

Prognostic factors of 'high-grade' Ta bladder cancers according to the WHO 2004 classification: are these equivalent to 'high-risk' non-muscle-invasive bladder cancer?

Paolo Gontero1, Arianna Gillo, Chiara Fiorito, Marco Oderda, Donatella Pacchioni, Giovanni Casetta, Francesca Peraldo, Andrea Zitella, Alessandro Tizzani, Fulvio Ricceri.   

Abstract

OBJECTIVE: To determine the impact of prognostic factors of a series of high-grade Ta non-muscle-invasive bladder cancers (NMIBCs) according to the new International Society of Urological Pathology (ISUP) 1998/WHO 2004 grading system (previously classified as either TaG2 or TaG3).
METHODS: One hundred and thirty-one high-grade Ta (105 G2 and 26 G3) cases were identified after independent review by two pathologists. Univariable and multivariable Cox regression models addressed recurrence and progression-free survival. Progression was defined as appearance of any T ≥1 recurrence after complete TUR (type 1) or occurrence of T ≥2 (type 2).
RESULTS: Ten-year recurrence, type-1 and type-2 progression-free survival were 60, 75 and 95%, respectively. The previous grading system (G3 vs. G2) significantly predicted type 1 progression in the univariate model only. In the multivariate model, Ki67 was the only independent predictor of progression according to both definitions (HR = 5.25, p = 0.002 and HR = 6.16, p = 0.03, respectively).
CONCLUSIONS: High-grade Ta NMIBC as defined by the WHO 2004 grading system cannot be equated with high-risk NMIBC. The risk of progression to muscle-invasive disease (type 2) is low, more in keeping with an intermediate-risk category of NMIBC. The previous WHO 1973 subcategorization into G2 and G3 is of little help in the prediction of outcome. Ki67 is a strong independent predictor of progression worthy of consideration for a clinical setting. 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2013        PMID: 24080613     DOI: 10.1159/000351961

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  4 in total

1.  Development and external validation of a nomogram to predict high-grade papillary bladder cancer before first-time transurethral resection of the bladder tumor.

Authors:  Ken Wakai; Takanobu Utsumi; Kei Yoneda; Ryo Oka; Takumi Endo; Masashi Yano; Masaaki Fujimura; Naoto Kamiya; Nobuyuki Sekita; Kazuo Mikami; Isamu Sugano; Nobuyuki Hiruta; Hiroyoshi Suzuki
Journal:  Int J Clin Oncol       Date:  2018-05-26       Impact factor: 3.402

2.  ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC).

Authors:  Johannes Breyer; Ralph M Wirtz; Mark Laible; Kornelia Schlombs; Philipp Erben; Maximilian Christian Kriegmair; Robert Stoehr; Sebastian Eidt; Stefan Denzinger; Maximilian Burger; Arndt Hartmann; Wolfgang Otto
Journal:  Virchows Arch       Date:  2016-08-11       Impact factor: 4.064

Review 3.  High Ki-67 Immunohistochemical Reactivity Correlates With Poor Prognosis in Bladder Carcinoma: A Comprehensive Meta-Analysis with 13,053 Patients Involved.

Authors:  Yihuan Luo; Xin Zhang; Meile Mo; Zhong Tan; Lanshan Huang; Hong Zhou; Chunqin Wang; Fanglin Wei; Xiaohui Qiu; Rongquan He; Gang Chen
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

Review 4.  Clinicopathological and Prognostic Value of Ki-67 Expression in Bladder Cancer: A Systematic Review and Meta-Analysis.

Authors:  Yuejun Tian; Zhiming Ma; Zhaohui Chen; Mingguo Li; Zhiping Wu; Mei Hong; Hanzhang Wang; Robert Svatek; Ronald Rodriguez; Zhiping Wang
Journal:  PLoS One       Date:  2016-07-13       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.